Advertisement

Archives of Pharmacal Research

, Volume 23, Issue 4, pp 418–423 | Cite as

Comparison between of the attenuated BR-Oka and the wild type strain of Varicella Zoster Virus (VZV) on the DNA level

  • Sang-Min Lim
  • Seong-Won Song
  • Sang-Lin Kim
  • Yoon-Jung Jang
  • Ki-Ho Kim
  • Hong-Jin Kim
Research Articles Biomedical Sciences
  • 83 Downloads

Abstract

Oka strain VR-795 (Varicella Zoster Virus, VZV) of American Type Culture Collection (ATCC) has been used for chickenpox vaccine production. In order to use this strain for vaccine production, the strain must be identified and its stability must be confirmed. The identification of the Oka strain has been confirmed using Restriction Fragment Length Polymorphism (RFLP) and DNA sequence analysis of glycoprotein-II (gp-II). The amino acid sequences of Oka deduced from the DNA sequence of gp-II have changed at three amino acids against Ellen and at one amino acid against Webster. To prove the stability of the Oka strain during the passage, RFLP and DNA sequence analyses were also used with 11, 15 and 23 times of virus passage. We found that the Oka strain was stable at passages of up to 23 times, based on the RFLP and DNA sequence analyses. The confirmed Oka strain was renamed as BR-Oka for the purposes of chickenpox vaccine production.

Key words

VZV Oka Chicken pox Vaccine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Davison, A. J. and Scott, J. E., The complete DNA sequence of varicella-zoster virus.J. Gen. Virol., 67, 1759–1816 (1986).PubMedCrossRefGoogle Scholar
  2. Hardy, I. and Gershon, A. A., Prospects for use of a varicella vaccine in adults.Infect. Dis. Clin. North Am., 4, 160–173 (1990).Google Scholar
  3. Hayakawa, Y., Torigoe, S., Shiraki, K., Yamanishi, K. and Takahashi, M., Biological and biophysical markers of a live varicella vaccine strain (Oka): Identification of clinical isolates from vaccine recipients.J. Infect. Dis., 149, 956–963 (1984).PubMedGoogle Scholar
  4. Hayakawa, Y., Yamamoto, T., Yamanishi, K. and Takahashi, M., Analysis of varicella-zoster virus DNAs of clinical isolates by endonuclease Hpal.J. Gen. Virol., 67, 1817–1829 (1986).PubMedCrossRefGoogle Scholar
  5. LaRussa, P., Lungo, O., Hardy, I., Gerrison, A. A., Steinberg, S. P. and Silverstein, S., Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates.J. Virol., 66, 1016–1020 (1992).PubMedGoogle Scholar
  6. Martin, J. H., Dohner, D. E., Wellinghof, W. J. and Gelb, L. D., Restriction endonuclease analysis of varicellazoster vaccine virus and wild-type DNAs.J. Med. Virol., 9, 69–76 (1982).PubMedCrossRefGoogle Scholar
  7. Sambrook, J., Fritisch, E. F. and Maniatis, T.,Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989.Google Scholar
  8. Shiraki, K., Horiuchi, K., Asano, Y., Yamanishi, K. and Takahashi, M., Differentiation of Oka varicella vaccine strain from wild varicella-zoster virus strains isolated from vaccinees and household contact.J. Med. Virol., 33, 128–132 (1991).PubMedCrossRefGoogle Scholar
  9. Straus, S. E., Owens, J., Ruyechan, W. T., Takiff, H. E., Casey, T. A., Vande Woude, G. F., and Hay, J., Molecular cloning and physical mapping of varicella-zoster virus DNA.Proc. Natl. Acad. Sci. USA., 79, 993–997 (1982).PubMedCrossRefGoogle Scholar
  10. Takahashi, M., Otsuka, T., Okuno, Y., Asano, Y., Yazaki, T. and Isomura, S., Live vaccine used to prevent the spread of varicella in children in hospital.Lancet 2, 1288–1290 (1974).PubMedCrossRefGoogle Scholar
  11. Takahashi, M., Okuno, Y., Ostsuka, T., Osame, J., Takamizawa, A., Sasada, T. and Kubo, T., Development of a live attenuated varicella vaccine.Biken J. 18, 25–33 (1975).PubMedGoogle Scholar
  12. Takahashi, M.,Advances in virus research, American Press, Vol 26, 285p-355p (1983).CrossRefGoogle Scholar
  13. Yoshizo, A., Takao, N., Takao, M., Takehiko, Y., Shigemitsu, I., Koichi, Y. and Michiaki, T., Long term protective immunity of recipients of the Oka strain of live varicella vaccine.PEDIATRICS, 75(4), 667–671 (1985).Google Scholar
  14. Weller, T. H., Serial propagation in vitro of agents producing inclusion bodies derived from varicella and herpes zoster.Proc. Soc. Exp. Bio. Med. 83, 340–346 (1953).Google Scholar
  15. White, C., Barbara, J., K., Carol, S., H., Kathryn, L., I., Varicella vaccine, VARIVAX, in health children and adolescents: Result from clinical trials, 1987 to 1989.PEDIATRICS 87 (5), 604–610 (1991)PubMedGoogle Scholar
  16. Wolfgang, K. J.,Virology, 3rd ED., Prentice-Hall, Englewood Cliffs, New Jersey, (1988).Google Scholar

Copyright information

© The Pharmaceutical Society of Korea 1999

Authors and Affiliations

  • Sang-Min Lim
    • 1
  • Seong-Won Song
    • 1
  • Sang-Lin Kim
    • 1
  • Yoon-Jung Jang
    • 2
  • Ki-Ho Kim
    • 2
  • Hong-Jin Kim
    • 2
  1. 1.Boryung Central Research InstituteBoryung Pharm. Co., Ltd.Ansan-Si, Kyungki-DoKorea
  2. 2.College of PharmacyChung Ang UniversitySeoulKorea

Personalised recommendations